Pickkers, Peter http://orcid.org/0000-0002-1104-4303
Angus, Derek C.
Bass, Kristie
Bellomo, Rinaldo
van den Berg, Erik
Bernholz, Juliane
Bestle, Morten H.
Doi, Kent
Doig, Chistopher J.
Ferrer, Ricard
Francois, Bruno
Gammelager, Henrik
Pedersen, Ulf Goettrup
Hoste, Eric
Iversen, Susanne
Joannidis, Michael
Kellum, John A.
Liu, Kathleen
Meersch, Melanie
Mehta, Ravindra
Millington, Scott
Murray, Patrick T.
Nichol, Alistair
Ostermann, Marlies
Pettilä, Ville
Solling, Christoffer
Winkel, Matthias
Young, Paul J.
Zarbock, Alexander
Carter, Angus
Fries, Dietmar
Eller, Philip
Gérard, Ludovic
DeSchryver, Nicolas
Diltoer, Elisabeth
Huberlant, Vincent
Michaux, Isabelle
Honore, Patrick M.
Fivez, Tom
Doig, Christopher
Wood, Gordon
Boyd, John
Turgeon, Alexis
Kamper, Maj
Strøm, Thomas
Iversen, Sussanne
Gammelager, Hendrik
Rasmussen, Bodil Steen
Sølling, Christoffer Grant
Mæller, Morten Hyllander
Groefte, Thorbjoern
Dey, Nilanjan
Pedersen, Ulf Gøttrup
Valkonen, Mila
Uusalo, Panu
Jalkanen, Ville
Meziani, Ferhat
Lemarie, Jermie
Plantefeve, Gaetan
Bachoumas, Konstantimos
Dufour, Jean Louis
Fedou, Anne-Laure
Asfar, Pierre
Monnet, Xavier
Vinsonneau, Christophe
Gibot, Sebastien
Guitton, Christophe
Quenot, Jean-Pierre
Muller, Gregoire
Lefrant, Jean Yves
Mercier, Emmanuelle
Mebazaa, Alexandre
Kortgen, Andreas
Fichtner, Sebastian
Kluge, Stefan
Marx, Gernot
Martin-Loeches, Ignatio
McNicolas, Bairbre
Kamohara, Hidenobu
Harada, Masahiro
Nakagami, Takuo
Adachi, Shingo
Ota, Kohei
Furuya, Ryo
Tsuruoka, Ayumu
Mizushima, Yasuaki
Inoue, Satoki
Tuinman, Pieter
Wim Roozendaal, F
Beishuizen, Bert
Hoiting, Oscar
Dormans, Tom
Van Zanten, Arthur
Young, Paul
Williams, Anthony
McArthur, Colin
Twardowski, Pawel
McGuinness, Shay
Roca, Ricard Ferrer
Cardenas, Carol Lorencio
Perez, Anna Navas
Sagasti, Fernando Martinez
Welters, Ingeborg
Wise, Matt
Waddy, Sam
MacCallum, Niall
Murugan, Raghaven
Gomez, Hernando
Busse, Larry
Boldt, David
Bernard, Andrew
Files, Daniel
Margolis, Benjamin
Mosier, Jarrod
Truwit, Jonathon
Zamora, Felix
Davison, Danielle
Exline, Matthew
Nielsen, Nathan
Hite, Duncan
,
Clinical trials referenced in this document:
Documents that mention this clinical trial
Phase-3 trial of recombinant human alkaline phosphatase for patients with sepsis-associated acute kidney injury (REVIVAL)
https://doi.org/10.1007/s00134-023-07271-w
Study protocol of a randomised, double-blind, placebo-controlled, two-arm parallel-group, multi-centre phase 3 pivotal trial to investigate the efficacy and safety of recombinant human alkaline phosphatase for treatment of patients with sepsis-associated acute kidney injury (Pre-results)
https://doi.org/10.1136/bmjopen-2022-065613
Article History
Received: 27 July 2023
Accepted: 9 November 2023
First Online: 3 January 2024
Change Date: 4 March 2024
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1007/s00134-024-07357-z
Declarations
:
: PP has received travel reimbursements and consulting fees from AM-Pharma in relation to his role as PI for REVIVAL, and consulting fees from Adrenomed, EBI Paion, Sphingotec, and 4Teen4 outside the submitted work. DCA has received consulting fees from AM-Pharma. KB, AM-Pharma BV, The Netherlands. RB has received consulting fees and research support from AM-Pharma, Baxter, Paion, Viatris, Jafron Biomedical, and CSL Behring. EvdB, AM-Pharma BV, The Netherlands. JB, AM-Pharma BV, The Netherlands. MHB has received consulting fees from AM-Pharma in relation to his role for REVIVAL and has conducted contract research for Inotrem outside of the submitted work. KD has received consulting fees from AM-Pharma. CJD reports no conflicts of interest. RF has received consulting fees from AM-Pharma. BF has received consulting fees from AM-Pharma as a member of the REVIVAL steering committee, and consulting fees from Inotrem, Aridis, and Enlivex outside the submitted work. HG reports funding from various companies in the form of research grants to (and administered by) Aarhus University or Aarhus University Hospital. HG has received support for attending meetings by Baxter A/S. UGP reports no conflicts of interest. EH has received a travel grant from AM-Pharma. SI reports no conflicts of interest. Michael Joannidis has received honoraria or research support from Baxter Healthcare Corp, AM-Pharma, CLS Behring, Fresenius, Takeda, Sanofi and Novartis. JAK discloses fees paid by AM-Pharma in relation to his role as national PI for REVIVAL and is currently a full-time employee of Spectral Medical. KL has been a member of the REVIVAL Steering Committee for AM Pharma. She has been a consultant/member of the DSMB for Seastar, Novartis, BOA Medical, Baxter, and Biomerieux, and she holds stock in Amgen. MM has received lecture fees from Baxter and Fresenius Medical Care. RM reports honoraria for consulting from Baxter, Biomerieux, Mallinckrodt, GE Healthcare, Sanofi, Abiomed, NovaBiomed, Renasym, and advisory board reimbursements from AM Pharma, Renibus, Alexion, Novartis, and Guard. SM reports no conflicts of interest. PTM has received consulting fees from AM-Pharma (for Clinical Trial Steering Committee activities), Novartis, Renibus Therapeutics, and Alexion. AN reports an unrestricted grant from Baxter to support the renal substudy of the TAME trial. MO has received speaker honoraria from Fresenius Medical, Baxter and Biomerieux; her institution received research funding from Baxter, Fresenius Medical, Biomerieux, and LaJolla Pharma. CS reports no conflicts of interest. PV reports no conflicts of interest. MW, AM-Pharma BV, The Netherlands. PJY has received consulting fees from AM Pharma and from Baxter Healthcare Pty. AZ has received consulting fees from Astute-Biomerieux, Baxter, Bayer, Novartis, Guard Therapeutics, AM Pharma, Paion, Renibus, Fresenius, research funding from Astute-Biomerieux, Fresenius, Baxter, and speakers fees from Astute-Biomerieux, Fresenius, Baxter.